Study on the effect of prednisolone on muscle strength and mobility

Glucocorticoids (GCs) are part of standard treatment in all AAV patients, regardless of induction and maintenance therapy. Unfortunately, GCs are associated with many short-term and long-term adverse effects. Patients in our center often report a decrease in leg muscle strength, resulting in difficulties standing up from a chair and walking up stairs. In this study, we aim to prospectively monitor the toxic effects of glucocorticoids in AAV patients treated for active disease. In particular, we will explore the effects on muscle strength, mobility and physical health status. These measurements could then be used for monitoring future interventions aimed at improving mobility of patients receiving glucocorticoid treatment.

-Patients experience decrease in muscle strength, mobility and physical health status during treatment with high-dose glucocorticoids for ANCA associated vasculitis

-The difference is clinically relevant, and some or all patients may require training exercises

T1=informed consent date, T2=4 weeks after start of treatment, T3=8 weeks after start of treatment, T4=12 weeks after start of treatment, T5=6 months after start of treatment

-Length will be measured at T1.

-SF-36 and Accelerometer measurements will be done at T1, T3 and T5

-All other measurements will be performed at all time points.

No interventions. Only additionional non-invasive measurements will be performed